- Policy
- A government-ruling party, pay attention to Syntekabio
- by Lee, Jeong-Hwan Oct 5, 2020 06:21am
- As it is known that the drug efficacy of the new drug substance for COVID-19 being developed by Syntekabio is more than twice that of Remdesivir, a government-ruling party is paying attention to this. On the 28th, Lee Nak-yeon, leader of the Democratic Party and Representative Han Jeoung-ae (General Manager of the National Disaster Recov
- Company
- Choline alfoscerate coverage reduction order suspended again
- by Chon, Seung-Hyun Oct 5, 2020 06:20am
- The court has once again approved to halt the administrative order on the cognitive enhancer ‘choline alfoscerate.’ Previously, the court has decided to suspend the order until the final ruling of the litigation, but another litigation case added 30 days to the already-approved order suspension. According to the industry sources on
- Policy
- Pfizer Korea withdraws a lot of OTC products
- by Lee, Tak-Sun Oct 5, 2020 06:20am
- Pfizer Korea has withdrawn a large number of domestic OTC products. There are only three items left. According to the MFDS on the 28th, Pfizer Korea recently withdrew permission for seven items, including Stresstabs Plus and Caltrate plus. Accordingly, only three items left by Pfizer Korea were Minulet, Alesse, and Cofrel. Even this is no
- Company
- Merged BMS-Celgene to offer ERP after all
- by Eo, Yun-Ho Oct 5, 2020 06:20am
- Initially merged with almost no downsizing, Bristol-Myers Squibb (BMS) and Celgene have ultimately decided to slim down the organization in South Korea. According to the pharmaceutical industry sources, BMS Korea has recently decided to issue the Early Retirement Program (ERP) as a result of acquiring Celgene. The staff reduction wou
- Policy
- Bavencio, listed on next month at ₩1,226,243/bottle
- by Kim, Jung-Ju Sep 29, 2020 06:21am
- Bavencio (Avelumab) by Merck, used for the treatment of metastatic Merkel cell carcinoma, will be covered by insurance benefits at &8361;1,226,243 per bottle starting next month. Since it is an expensive drug, it will follow the RSA track, and will be listed as a refund type in which pharmaceutical companies reimburse a certain percent
- Policy
- Kwang Dong competes with Elyson for Nebivolol
- by Lee, Tak-Sun Sep 29, 2020 06:21am
- Kwang Dong is challenging the market by obtaining approval for all three high and low doses of the hypertension treatment 'Nebivolol HCl'. This is the second case that 3 doses have been approved since Elyson was approved. On the 28th, the MFDS approved Kwang Dong's Nebilet M 1.25mg, 2.5mg and 5mg. Nebilet M is a generic for Menarini's Nebile
- Company
- Ildong is accelerating the development of Lasmiditan
- by Kim, Jin-Gu Sep 29, 2020 06:20am
- Ildong is accelerating the development of a new class of migraine treatment 'Lasmiditan'. A large-scale phase III clinical trial is in progress, close to 300 as a bridged clinical trial, and it is confirmed that the registration of subjects has recently been completed. According to the pharmaceutical industry on the 25th, Ildong recent
- Company
- Korean rare disease drug Hunterase market share surges
- by An, Kyung-Jin Sep 29, 2020 06:20am
- Developed with South Korean-made rare disease treating technology, Hunterase (idursulfase-β) continues to top the market. The treatment’s market share gap with Elaprase (idursulfase) that used to dominate the Hunter syndrome market has tripled as Hunterase maintains market share of over 70 percent. While the treatment is generating signifi
- Opinion
- [Reporter’s view] Nikola and Korean Pharmaceutical Market
- by Kim, Jin-Gu Sep 28, 2020 06:21am
- Money flows into unsubstantiated expectations. Money begets money. The stock value jumped over the moon. Before long, It came to light. Stock prices plummeted, and investors fell into despair. It is a story about the American hydrogen truck company 'Nikola'. It was once called the second Tesla and received the attention of investors, but o
- Company
- Pfizer Korea launches Cresemba in Korea
- by Eo, Yun-Ho Sep 28, 2020 06:20am
- Pfizer Korea launched Cresemba (Isavuconazole), an invasive fungal infection treatment in Korea. Cresemba is an antifungal drug approved for the treatment of invasive aspergillosis in adults over 18 years of age and invasive mucormycosis, which is not suitable for administration of Amphotericin B in adults over 18 years of age, and obtain
